AC Immune SA Files 6-K, Includes 2023 Annual Report
Ticker: ACIU · Form: 6-K · Filed: Mar 14, 2024 · CIK: 1651625
| Field | Detail |
|---|---|
| Company | Ac Immune SA (ACIU) |
| Form Type | 6-K |
| Filed Date | Mar 14, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: annual-report, press-release, filing
TL;DR
AC Immune SA dropped its 2023 annual report and a March 14 press release via a 6-K filing.
AI Summary
AC Immune SA filed a Form 6-K on March 14, 2024, to report its 2023 Annual Report and a press release dated March 14, 2024. The filing includes information about the company's principal executive offices located at EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland. The report was signed by CEO Andrea Pfeifer and CFO Christopher Roberts.
Why It Matters
This filing provides investors with the company's latest annual performance data and recent press releases, offering insights into its financial health and strategic developments.
Risk Assessment
Risk Level: low — This filing is a routine submission of an annual report and press release, not indicating any immediate operational or financial distress.
Key Players & Entities
- AC Immune SA (company) — Registrant
- Andrea Pfeifer (person) — Chief Executive Officer
- Christopher Roberts (person) — Chief Financial Officer
- March 14, 2024 (date) — Filing Date
FAQ
What is the purpose of this 6-K filing?
The purpose of this 6-K filing is to report the registrant's 2023 Annual Report and a press release dated March 14, 2024, as required by the Securities Exchange Act of 1934.
Who signed this report on behalf of AC Immune SA?
The report was signed by Andrea Pfeifer, Chief Executive Officer, and Christopher Roberts, Chief Financial Officer.
What is the address of AC Immune SA's principal executive offices?
The principal executive offices are located at EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland.
What exhibits are included with this 6-K filing?
The included exhibits are Exhibit 99.1 (Press Release dated March 14, 2024) and Exhibit 99.2 (2023 Annual Report).
What is the SEC file number for AC Immune SA?
The SEC file number for AC Immune SA is 001-37891.
Filing Stats: 164 words · 1 min read · ~1 pages · Grade level 13.2 · Accepted 2024-03-14 07:44:21
Filing Documents
- tm2328688d2_6k.htm (6-K) — 10KB
- tm2328688d2_ex99-1.htm (EX-99.1) — 126KB
- tm2328688d2_ex99-2.pdf (EX-99.2) — 3247KB
- tm2328688d2_ex99-1img001.jpg (GRAPHIC) — 8KB
- 0001104659-24-034238.txt ( ) — 4610KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AC IMMUNE SA By: /s/ Andrea Pfeifer Name: Andrea Pfeifer Title: Chief Executive Officer By: /s/ Christopher Roberts Name: Christopher Roberts Title: Chief Financial Officer Date: March 14, 2024 EXHIBIT INDEX Exhibit Number Description 99.1 Press Release dated March 14, 2024 99.2 2023 Annual Report